drug

Omega-3 fatty acids

Omega-3 Fatty Acids
as of 2026-07-01
Add to landscapeMonitor thisCompare thisAsk about this
at a glance
small molecule
Pre-approval / investigational in the US
Developed by Pakistan Institute of Living and Learning
3 trials in the graph
Synthesized from structured facts only — each point cited above.

Mechanism & identity

Modality
small molecule

Indications

Trials

3
Placebo-controlled Trial in Subjects at Ultra-high Risk for Psychosis With Omega-3 Fatty Acids in Europe
NCT02597439Phase 4Completed
Minocycline and/or Omega-3 Fatty Acids Added to Treatment as Usual for At Risk Mental States
NCT02569307Phase 2Completed
Omega-3 Fatty Acid Deficiency Replacement in Early Schizophrenia
NCT00585390Phase 2, Phase 3Completed

KOLs & investigators

3
René Kahn, Prof. Dr.KOL score 11
Dr.Inti Qurashi, MDKOL score 5
Neil Richtand, MD

Facts & assertions

0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
Pakistan Institute of Living and Learning
company
trial
Placebo-controlled Trial in Subjects at Ultra-high Risk for Psychosis With Omega-3 Fatty Acids in Europe
PHASE4
trial
Minocycline and/or Omega-3 Fatty Acids Added to Treatment as Usual for At Risk Mental States
PHASE2
trial
Omega-3 Fatty Acid Deficiency Replacement in Early Schizophrenia
PHASE2, PHASE3
trial
indication
Schizophrenia
indication
Psychosis
indication
Fatty Acid Deficiency
indication
Schizophrenia
indication
KOL
René Kahn, Prof. Dr.
KOL score 11
person
Dr.Inti Qurashi, MD
KOL score 5
person
Neil Richtand, MD
KOL score —
person